Status:
UNKNOWN
Safety and Efficacy of Remote Ischemic Conditioning Combined EDAS on Ischemic Moyamoya Disease
Lead Sponsor:
Capital Medical University
Collaborating Sponsors:
Beijing 302 Hospital
Conditions:
Moyamoya Disease
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
Encephaloduroarteriosynangiosis (EDAS) is widely used as an indirect technique for treatment of moyamoya disease. Nevertheless, this indirect surgery tends to establish insufficient collateral circula...
Detailed Description
Encephaloduroarteriosynangiosis (EDAS) is widely used as an indirect technique for treatment of moyamoya disease. Nevertheless, this indirect surgery tends to establish insufficient collateral circula...
Eligibility Criteria
Inclusion
- Subjects who were diagnosed as moyamoya disease by the diagnostic criteria recommended by the Research Committee on MMD of the Ministry of Health and Welfare of Japan in 2012.
- Suzuki stage: 2-5 stage
- Age: between 18 and 65 years old
- Subjects present with ischemic stroke or transient ischemic attack.
- Subjects who plan to accept the first EDAS surgery.
- Informed consent obtained from patient or patient's surrogate
Exclusion
- Acute ischemic stroke occurred within one month.
- Suffered Intracranial hemorrhage before
- Subjects with large infarction spread widely over the territory of a main arterial trunk
- Aneurysms in the main arterial trunk
- Severe cardiac diseases like atrial fibrillation，valvular disease，heart failure, infective endocarditis and so on.
- Malignant tumors or severe disordered function of the heart, lung, liver or kidney.
- Severe hemostatic disorder or severe coagulation dysfunction.
- Uncontrolled diabetes mellitus with a serum fasting blood glucose level\>300 mg/dL, or requires insulin; hypertension with a systolic blood pressure over 180 mmHg or a diastolic blood pressure over 110 mmHg.
- Severe injury on upper limbs.
- Pregnant or lactating women.
- Life expectancy is less than 3 years.
- Patients who are not suitable for this trial considered by researchers for other reasons
Key Trial Info
Start Date :
June 15 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 30 2022
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT04917003
Start Date
June 15 2021
End Date
June 30 2022
Last Update
June 29 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The 307th Hospital of the Chinese People's Liberation Army
Beijing, China, 100071